MDM2: current research status and prospects of tumor treatment
Cancer Cell International · 13.05.2024 · 24 (1)
DOI: 10.1186/s12935-024-03356-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cell International, online erschienen am 13.05.2024. Verfasst von Yumei Yao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Zhaotong Health Vocational College, No 603 Yucai Road, Zhaotong City, Yunnan Province, 657000, People's Republic of China. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mousedouble minute 2 (MDM2) is one of the molecules activated by p53 and plays an important role in the regulation of p53. MDM2 is generally believed to function as a negative regulator of p53 by facilitating its ubiquitination and subsequent degradation. Consequently, blocked p53 activity often fails in damaged cells to undergo cell cycle arrest or apoptosis. Given that around 50% of human cancers involve the inactivation of p53 through genetic mutations, and directly targeting p53 through drug development has limited feasibility, targeting molecular regulation related to p53 has great potential and has become a research hotspot. For example, developing drugs that target the interaction between p53 and MDM2. Such drugs aim to reactivate p53 by targeting either MDM2 binding or p53 phosphorylation. Researchers have identified various compounds that can serve as inhibitors, either by directly binding to MDM2 or by modifying p53 through phosphorylation. Furthermore, a significant correlation exists between the expression of MDM2 in tumors and the effectiveness of immunotherapy, predominantly in the context of immune checkpoint inhibition. This review presents a comprehensive overview of the molecular characteristics of MDM2 and the current state of research on MDM2-targeting inhibitors. It includes a review of the impact of MDM2 targeting on the efficacy of immunotherapy, providing guidance and direction for the development of drugs targeting the p53-MDM2 interaction and optimization of immunotherapy.
Autor:innen und Institutionen
- Zhaotong Health Vocational College, No 603 Yucai Road, Zhaotong City, Yunnan Province, 657000, People's Republic of China.
- Zhaotong Health Vocational College, No 603 Yucai Road, Zhaotong City, Yunnan Province, 657000, People's Republic of China. 15111010041@fudan.edu.cn.
- Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming, Yunnan, 650302, People's Republic of China. 15111010041@fudan.edu.cn.
Zitieren
APA
Yao, Y., Zhang, Q., Li, Z., & Zhang, H. (2024). MDM2: current research status and prospects of tumor treatment. Cancer Cell International, 24(1). https://doi.org/10.1186/s12935-024-03356-8
Vancouver
Yao Y, Zhang Q, Li Z, Zhang H. MDM2: current research status and prospects of tumor treatment. Cancer Cell International. 2024;24(1). doi:10.1186/s12935-024-03356-8
BibTeX
@article{Yao2024,
author = {Yao, Yumei and Zhang, Qian and Li, Zhi and Zhang, Hushan},
title = {MDM2: current research status and prospects of tumor treatment},
journal = {Cancer Cell International},
year = {2024},
volume = {24},
number = {1},
doi = {10.1186/s12935-024-03356-8}
}
EUVIMED